Shared decision-making in NSCLC
Released On
March 17, 2025
Expires On
March 17, 2026
Media Type
Internet
Completion Time
15 minutes
Specialty
Hematology & Oncology, Pathology, Pharmacy, Pulmonology
Topics
Lung Cancer
Acknowledgement
This independent medical education program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Credit Available
- Physicians — maximum of 0.25 AMA PRA Category 1 Credit™
- Nurses — 0.25 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of oncologists, pathologists and those treating patients with NSCLC worldwide.
Program Overview
This activity will help you learn how to implement effective multidisciplinary collaboration to improve care for patients with biomarker-positive NSCLC.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the key elements of shared decision-making and its role in patient-centered care for NSCLC
- Apply clear and effective communication strategies when explaining biomarker testing and treatment options to patients
- Utilize educational tools and resources to help patients engage in a shared decision-making approach when selecting a management strategy
Faculty
Dr. Xiuning Le
As an Associate Professor and Deputy Section Chief in the Thoracic/Head and Neck department Dr. Le has contributed her knowledge via trials, clinical journals and lectures with focus non-small cell lung cancer with actionable oncogenes.
Dr. Le earned her medical degree from the Peking Union Medical College. She then went on to earn a degree in Biological and Biomedical Sciences at Harvard Medical School in Boston. She completed her internship and residency at The University of Massachusetts Medical Center in Worcester, MA, an additional residency at the University of Texas. Prior to joining the staff at M.D. Anderson, she also completed a fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Board certified in both internal medicine and medical oncology, Dr. Le specializes in thoracic, head, and neck oncology.
Dr. Le has led clinical trials resulted in FDA approval of novel targeted therapies in lung cancer. She has published more than 120 articles in the field of lung and head and neck cancer. She was first- or last author of many high-impact papers, including New England Journal of Medicine, Cancer Discovery, Clinical Cancer Research and Journal of Thoracic Oncology.
Dr. Le received the ASCO Young Investigator Award, SU2C-TVF Convergence Program, Claudia Adams Barr for Innovative Cancer Research, ASCO Career Development Award, Paul Calabresi NIH K12 Award, Damon Runyon Award, V Foundation Award, and Sabin Award, and more.
Accreditation Statement
This activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Springer Healthcare IME. PIM is committed to ensuring that all jointly provided activities are planned and implemented in accordance with the requirements of the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center Commission on Accreditation (ANCC), and the Accreditation Council for Pharmacy Education (ACPE), or other accrediting body, as appropriate to the type of credit to be provided by the activity.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Springer Healthcare IME planners and others have nothing to disclose.
All relevant financial relationships have been mitigated.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.
Disclosure of Conflicts of Interest
Dr Xiuning Le:
- Research grants/support from: Lilly, Roche, Thermo Fisher Scientific
- Honoraria or consultation fees: Lilly, Roche, Thermo Fisher Scientific, Astra Zeneca, Bayer, Takeda, Janssen, MSD, BMS, Pfizer
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Complete the activity module
- Fill out the short evaluation form at the end of the module. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]